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Circulating levels of triacylglycerol (TG) is a recognized risk factor for developing cardiovascular disease, a leading
cause of death worldwide. The Institute of Medicine and the American Heart Association both recommend the
consumption of n-3 polyunsaturated fatty acids (PUFA), specifically eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), to reduce serum TG in hyperlipidemic individuals. Additionally, a number of systematic reviews have shown
that individuals with any degree of dyslipidemia, elevated serum TG and/or cholesterol, may benefit from a
20-30 % reduction in serum TG after consuming n-3 PUFA derived from marine sources. Given that individuals
with serum lipid levels ranging from healthy to borderline dyslipidemic constitute a large portion of the population, the
focus of this review was to assess the potential for n-3 PUFA consumption to reduce serum TG in such individuals. A total
of 1341 studies were retrieved and 38 clinical intervention studies, assessing 2270 individuals, were identified for inclusion
in the current review. In summary, a 9-26 % reduction in circulating TG was demonstrated in studies where≥ 4 g/day of
n-3 PUFA were consumed from either marine or EPA/DHA-enriched food sources, while a 4-51 % reduction was found in
studies where 1–5 g/day of EPA and/or DHA was consumed through supplements. Overall, this review summarizes the
current evidence with regards to the beneficial effect of n-3 PUFA on circulating TG levels in normolipidemic to borderline
hyperlipidemic, otherwise healthy, individuals. Thus demonstrating that n-3 PUFA may play an important role in
the maintenance of cardiovascular health and disease prevention.
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Cardiovascular disease (CVD) is one of the leading causes
of mortality in North America, accounting for 1/3 and 1/6
of all deaths in Canada and the United States, respectively
[1, 2]. Elevated levels of circulating triacylglycerol (TG) have
been identified as an independent risk factor for developing
CVD; evidence from Hokanson et al. indicates that an
88 mg/dL increase in fasting TG levels elevates the risk of
developing CVD by 14 % and 37 %, in males and females,
respectively [3–8]. Additionally, a large proportion of
Canadians and Americans (26 % and 14 %, respectively)* Correspondence: davidma@uoguelph.ca
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(http://creativecommons.org/publicdomain/zerohave been reported to be either hypertriglyceridemic or
hyperlipidemic [2, 9, 10]. Omega 3 (n-3) polyunsaturated
fatty acids (PUFA) have well-established TG lowering ef-
fects in hyperlipidemic individuals which may extend to
normolipidemic populations [11–19].
The 2002 Institute of Medicine (IOM) report on Dietary
Reference Intakes for various macronutrients, including fat,
states that, “Supplementation with fish oil, which is high in
EPA and DHA, reduces triacylglycerol concentrations; low
density lipoprotein cholesterol and high density lipoprotein
cholesterol concentrations are either increased or un-
changed” [11]. Food and supplement based studies asses-
sing the lipid-lowering effects of n-3 PUFA have utilized a
variety of oils comprised of either flaxseed-derived alpha-
linolenic acid (18:3 n-3, ALA), algal-derived pure eicosa-
pentaenoic acid (20:5 n-3, EPA) or docosahexaenoic acidicle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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through the consumption of fish or fish oils. It is therefore
important to determine which forms of n-3 PUFA, or com-
bination of forms, are bioactive in affecting serum TG levels
and to detect differences in efficacy among various forms.
Systematic reviews by Wei and Jacobson, Bernstein et al.,
and Eslick et al. highlight the lipid-lowering capacity of dif-
ferent sources and forms of n-3 PUFA in populations that
range from normolipidemic to hyperlipidemic [20–22].
Wei and Jacobson compared the efficacy of DHA to EPA
and found that individuals who consumed either DHA or
EPA experienced reductions in serum TG of 18.5 % and
32 %, respectively. Individuals also exhibited significantly
elevated serum low density lipoprotein cholesterol (LDL-c)
levels by 5 % after DHA consumption, while those consum-
ing EPA had a non-significant reduction in serum LDL-c of
1 % [20]. Additionally, Bernstein et al. concluded that DHA
from algal oil plays a role in reducing serum TG while ele-
vating serum LDL-c [21]. The results of a systematic review
by Eslick et al. showed that 3.25 g/day of fish oil (1.9 g of
EPA and 1.35 g of DHA) reduced serum TG by 14 %, yet
cholesterol levels were not altered beyond a clinically insig-
nificant increase in LDL-c [22]. Similar results were ob-
tained in systematic reviews by Balk et al. and Mori et al.,
both of which assessed studies in which individuals con-
sumed either fish, algal EPA or algal DHA oils [23, 24].
While results from the previously identified systematic re-
views indicate that DHA contributes to slight increases in
LDL-c and EPA contributes to minor reductions in LDL-c,
both n-3 PUFA were established to be efficacious in signifi-
cantly lowering serum TG levels.
The previously discussed meta-analyses and systematic
reviews concur with the observation that EPA and DHA,
derived from fish or algal oils, can reduce serum lipids,
most notably TG. However, these analyses primarily fo-
cused on hyperlipidemic individuals, a population likely to
achieve the most drastic reduction in TG levels upon n-3
PUFA consumption, and may conceal a lack of response in
normolipidemic subjects, whom with they were pooled
[18]. The purpose of the current review is to provide new
knowledge with regards to our understanding of the effect
of dietary and supplemental n-3 PUFA intake on blood
lipid profiles in healthy individuals, using the 2002 IOM
report as a reference point. A focus will be placed on the
TG-lowering ability of n-3 PUFA in normal to borderline
hyperlipidemic populations as defined by AHA guidelines.
Methods
Search strategy
Using the PubMed search engine, clinical trials and obser-
vational studies relating to the effects of n-3 PUFA on
serum biomarkers of CVD were collected. Search terms
(described below) were used to gather studies published
from January 1, 2000 – October 1, 2013 as they were notcaptured within the reference point of the 2002 IOM
report. Search terms relating to cholesterol, C-reactive pro-
tein (CRP) and chronic illnesses were used to capture the
entirety of literature analyzing blood lipids as such studies
would likely have included TG measurements (Fig. 1 sum-
marizes the search strategy).
Search terms:
(1)n-3 OR omega 3 OR EPA OR eicosapentaenoic acid
OR DHA OR docosahexaenoic acid OR ALA OR
alpha-linolenic acid
AND
(2)dyslipidemia OR total cholesterol OR cholesterol
OR LDL cholesterol OR HDL cholesterol OR
triacylglycerol OR CRP
AND
(3)heart disease OR CVD OR cardiovascular disease
OR stroke OR diabetes OR obesity
This search returned 1341 results on PubMed. An initial
screen of the title and abstract for relevancy was conducted
based on the following inclusion and exclusion criteria:
Inclusion criteria
 Published between 1/1/2000 and 1/10/2013
 Human participants
 Article written in English
 Adult participants aged >18 years
Exclusion criteria
 In vitro studies
 Participants were suffering from or had a history of
chronic illness (i.e. CVD, type 2 diabetes, cancer, etc.)
 Participants were medicated – not including
hormone replacement therapy (HRT)
 Reviews and meta-analyses
Based on the above, 514 published studies (collected
by two independent researchers) were reviewed in detail
and 207 clinical trials were identified for further consid-
eration. The final list of clinical trials was selected based
on the following inclusion and exclusion criteria:
Inclusion criteria:
 Healthy participants, defined as:
 Healthy or moderately hyperlipidemic participants
according to the American Heart Association
(AHA) guidelines [plasma lipid levels for
borderline hyperlipidemic individuals are:
Fig. 1 Flow chart of the study selection and exclusion methodology
Leslie et al. Lipids in Health and Disease  (2015) 14:53 Page 3 of 18200 ≤ total-cholesterol (total-c) ≤ 240 mg/dL,
130 ≤ LDL-c ≤ 160 mg/dL, and 150 ≤ TG
≤ 200 mg/dL] [14, 25]
 Healthy or overweight participants: Mean BMI
within intervention group(s) and control/placebo
group (if applicable) at baseline ≤29.9 kg/m2
 Study end-points included blood lipid parameters
(TG, total-c, high-density lipoprotein cholesterol
(HDL-c), LDL-c)*
 Study must involve a dietary or supplement
intervention with n-3 PUFA
 Study duration was at least 2 weeks
Exclusion criteria
 Participants that fulfilled the inclusion criteria
were analyzed with participants that wereexplicitly stated to have not met the inclusion
criteria
 Endpoints were analyzed ex vivo
 Low quality studies**
*Studies that did not report a baseline profile for
total-c, LDL-c and/or TG were included in analysis if
they fulfilled all remaining inclusion and exclusion cri-
teria described above.
**Study quality was assessed by the Appraisal guide for
intervention/experimental studies provided by Health
Canada [26], if studies scored below a threshold of seven
they were excluded from the current review (a single study
scored below this threshold).
Applying these parameters yielded 38 clinical trials
that were further stratified into dietary interventions
(16 studies) and supplementation trials (22 studies).
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Dietary interventions
Using the indicated selection criteria, 16 dietary inter-
vention studies (633 subjects in total) were deemed ap-
propriate for the assessment of the impact of n-3 PUFA
consumption on circulating TG and cholesterol levels
within normolipidemic and borderline hyperlipidemic
(otherwise healthy) adults (Table 1). It is noteworthy that
two of the 16 studies [27, 28] were subsequent analyses
of formerly identified interventions [29, 30]. Therefore,
they are presented as single experiments in this review.
As a result, a final list of 14 unique dietary intervention
studies were assessed (Table 1). Among the 14 dietary
intervention studies, four studies utilized increased fish
consumption [31–34]; five studies examined the benefits
of increasing EPA/DHA intake by enriching foods to
contain a higher content of n-3 PUFA [27, 29, 35–38];
three studies measured the effects of increasing ALA in-
take [28, 30, 39, 40]; and 2 studies altered the n-6:n-3
PUFA ratio while maintaining a constant amount of n-3
PUFA consumption [41, 42]. Alterations from baseline
plasma TG and cholesterol values were assessed in all 14
intervention studies in the current review. Overall, of
the 24 experimental arms within the 14 studies, 15
showed reduced serum TG levels (five were statistically
significant reductions; Table 2) and eight of the 14 stud-
ies showed reduced serum total-c, LDL-c or both (five
were statistically significant reductions; Table 1). The
three dietary interventions that provided ≥ 4 g/day of
EPA and/or DHA noted significant reductions in TG of
9-26 % [27, 29, 31, 33], while six out of seven experi-
mental arms providing 2.3-3.4 g/day of marine based
n-3 PUFA produced non-significant reductions in TG of
3-14 % [32, 34, 42], and the effect of n-3 PUFA provided
from flaxseed, flaxseed oil or ≤ 2 g/day of EPA and/or
DHA remains ambiguous [28, 30, 35–40].
TG and LDL-c were only significantly lowered in in-
terventions providing more than 4 g/day of n-3 PUFA
through increased fish consumption. Two trials, of
4 weeks [31] and 8 weeks in duration [32], showed that
fish consumption of 125–150 g/day (3.4-5.4 g/day of n-3
PUFA) reduced TG levels by 14-15 %. The 4-week inter-
vention also showed a statistically non-significant 7 %
reduction in LDL-c [31]. Another study demonstrated
that switching from a Swedish diet to a Mediterranean
diet (2.3 g vs. 4.1 g/day of n-3 PUFA) for 4 weeks re-
sulted in statistically significant 17 %, 23 % and 17 % re-
ductions in serum total-c, LDL-c and TG, respectively
[33]. Finally, participants consuming an oily fish diet
(2.6-3.0 g/day of n-3 PUFA) for 8 weeks experienced
non-significant reductions in total-c and LDL-c by 2.3 %
and 7.5 %, respectively, and a trend towards lowered TG
levels (by 3.1 %) was observed when compared to a red
meat diet (1.2-1.4 g/day of n-3 PUFA) [34].There were five studies designed to increase EPA and/
or DHA consumption through enriched baked goods
[27, 29], drinks [35–37], or pork derived from animals
consuming marine based n-3 PUFA-enriched food [38].
Two 12 week studies, one providing 0.86 g/day of n-3
PUFA from enriched milk and the other providing
0.185 g/day of n-3 PUFA from enriched pork, produced
significant reductions in serum TG of 17 % and 27 %, re-
spectively, while not significantly altering serum choles-
terol levels [37, 38]. One 8-week intervention providing
0.33 g/day of n-3 PUFA from enriched milk showed a re-
duction in total-c and LDL-c of 6 % and 16 %, respectively
[35]; while a second 8-week study providing 4 g/day of n-3
PUFA from enriched baked goods produced a statistically
significant 26 % reduction in TG levels [27, 29]. In contrast,
a 2-week study providing 0.5 g/day of n-3 PUFA from EPA/
DHA enriched tomato juice did not report any changes in
TG or cholesterol levels, however, participants show signifi-
cant reductions in circulating homocysteine, VCAM-1 and
ICAM-1 [36].
Studies assessing an increased consumption of ALA
utilized 30–40 g/day of flaxseed (5.74-8.42 g/day of ALA)
[28, 30, 39, 40], yet the results from these trials produced
inconsistent effects on lipid levels. For instance, a 4-week
intervention with 32.7 g/day of ground flaxseed led to a
41 % increase in TG levels [39]. In contrast, a 12-month
intervention, providing 40 g/day of flaxseed, resulted in the
maintenance of cholesterol and TG levels, while the pla-
cebo significantly elevated plasma total-c and LDL-c levels
[28, 30]. Additionally, one 4-week intervention that pro-
vided participants with 5.74-6.5 g/day of ALA found non-
significant reductions in serum lipids [40]. Interestingly,
although non-significant, the consumption of ground flax-
seed or flaxseed oil (each providing an equal amount of
ALA) resulted in 11 % and 20 % reductions in TG levels,
respectively, in individuals 18–29 years of age; ground flax-
seed also led to 7 % and 12 % reductions in total-c and
LDL-c, respectively [40].
All of the previously mentioned studies reduced an in-
dividual’s dietary n-6:n-3 PUFA ratio by elevating n-3
PUFA consumption. However, two studies investigated
the effects of altering the n-6:n-3 PUFA dietary ratio by
increasing n-6 PUFA intake while maintaining a con-
stant n-3 PUFA intake. This allowed for the investigation
into whether a reduced n-6:n-3 PUFA ratio alone is
more beneficial than an absolute increase in n-3 PUFA
consumption as well as a decreased dietary n-6:n-3
PUFA ratio, as evaluated in the previous studies. One
study accomplished this by replacing monounsaturated
fatty acids with n-6 PUFA; participants either consumed
a moderate or high ratio of n-6:n-3 PUFA consisting of
15 g or 26 g/day, respectively, of n-6 PUFA while con-
sistently consuming 2 g/day of n-3 PUFA for 6 weeks
[41]. While there were no statistically significant










16 males, 32 females 125 g of salmon
(5.4 g of n-3 PUFA)
Intervention (no
placebo)
4 week intervention; 4 week
washout without fish
TG reduced 15 % (sig) Blood pressure reduced 4 %
(sig)
Scottish
LDL-c reduced 7 %
20–55 yrs old Adiponectin reduced
(TG – 83, Total-C -
167, LDL-C - 92)
HDL-c elevated 5 % (sig)
Hallund
(2010) [32]
68 males 150 g of trout fed





TG reduced 14 % and 6 %
in participants consuming
trout fed marine-based diet
and trout fed a vegetable-
based diet, respectively
Trout fed marine-based diet
resulted in a reduction of
blood pressure and CRP,




(TG – 102, Total-C -
189, LDL-C - 117)
Vs.
150 g of trout fed




12 males, 10 females Mediterranean diet
(4.1 g n-3 PUFA)
Randomized,
cross-over trial
4 week on one diet, 4 week
washout, 4 week on opposite diet
TG reduced 9 % in the
group receiving
Mediterranean diet
Consumed fewer calories on
Mediterranean vs. Swedish




30–51 yrs old Swedish diet (2.3 g n-3
PUFA)
Switching from a Swedish diet to a
Mediterranean diet reduced serum
TG, Total-c and LDL-c by 17 %,
17 % and 23 %, respectively (sig)
(TG – 97, Total-C -
217, LDL-C - 139) Source of n-3 PUFA in










8 weeks per diet TG reduced 3.1 % while on fish diet TG and HDL-c increased by
7.9 % and HDL-c by 1.2 %
while on red meat diet
18–30 yrs old
(TG – 60, Total-C -
173, LDL-C - 97)
Vs.
Total-c and LDL-c reduced 2.3 %
and 7.5 %, respectively, while HDL-c
increased by 7.2 %, while on fish
diet (sig)




15 males, 15 females
(low background
daily fish intake)
500 ml of n-3 PUFA
enriched semi-skimmed




4 week run in on low fish diet,
8 weeks consuming enriched milk
Total-c and LDL-c decreased 6 and
16 % (sig)
Homocysteine and VCAM-1




(TG – 108, Total-C -





















79 males Bakery products
supplemented with
33 g of experimental fats:




8 weeks TG reduced 26 % f baseline in
the n-3 PUFA grou hange was
significantly greate an the TG
reduction observe
the control group.
The n-3 PUFA diet resulted in
a 3 beat/min reduction in
heart rate of subject with a




HDL-c reduced in group
receiving soy oil co ared to the
control
(TG – 102, Total-C -
185, LDL-C - 116) (b) 12 g fish oil (4 g n-3
PUFA);
Vs.





18 females 2 glasses of 250 ml n-3
PUFA-enriched tomato









Vs.(TG – 59, Total-C -
197, LDL-C - 113) Placebo
Hamazaki
(2003) [37]







12 weeks TG levels reduced % (sig) in the
group receiving th -3 PUFA
enriched soybean k (no changes
observed in the ol oil enriched milk)
Japanese
43–59 yrs old Fish oil (0.6 g EPA +
0.26 g DHA)(TG – 154, Total-C -
211, LDL-C - 127) Vs. LDL-c levels did no hange, while




29 males 200 g portion of pork
from pigs fed a diet







12 weeks TG levels reduced % in the
group consuming n-3 PUFA
fortified pork comp d to controls
The n-3 PUFA fortified pork
diet resulted in an elevation
of serum thromboxane






15 males 3 flaxseed-enriched muf-




4 weeks TG elevated 41 % )
Canadian
22–47 yrs old
(TG – 124, Total-C -















12 months Flaxseed-enriched ad raised the
participants’ serum 3 %
Flaxseed bread reduced BMI
from baseline values (sig)
French Canadian
49–65 yrs old Vs. LDL-c reduced in t group receiving
flaxseed bread com red to the
placebo
(TG – 101, Total-C -
221, LDL-C - 134)














































4 weeks Diet (A) decreased total-c,
LDL-c and TG by 7 %,
12 % and 11 % respectively,
in Group 1. In group 2,
Diet A decreased total-c and
LDL-c 2 % while elevating TG
by 13 %




(TG – 91, Total-C -
165, LDL-C - 78)






(TG – 81, Total-C -
181, LDL-C - 99)
B) Flaxseed oil (5.74 g of
ALA)
Diet (B) decreased TG 20 % in Group




19 males n-3 PUFA-enriched cook
ing oil and margarine





6 weeks A diet containing a moderate ratio
of n-6:n-3 PUFA resulted in 3 % and 8 %
reductions in total-c and LDL-c,
respectively, while increasing HDL-c
by 8 % (0.05 < p < 0.1)
Diet providing a moderate
ratio of n-6:n-3 PUFA
increased total n-3 PUFA
within RBC
Indian Asian (in the
UK)
35–70 yrs old Diet providing a high ratio of
n-6:n-3 PUFA increased plasma
insulin levels and the
participant’s HOMA-IR index
(sig)
Moderate n-6:n-3 (15 g
n-6 PUFA)(TG – 140, Total-C -
192, LDL-C - 120) Vs.




12 males, 8 females Gilthead sea bream fillets
(2.3 g n-3 PUFA) fed






15 day run in with no fish
consumption, 10 weeks on
fishmeal fed fish followed by
10 weeks on plant protein fed
fish (or vice versa)
TG, total-c and LDL-c decreased
11.7 %, 29.3 % and 21.6 %,
respectively, in group first receiving
fishmeal fed fish (sig). Values
rebounded to normal following
second dietary intervention
Group first receiving fishmeal
fed fish experienced
reductions in IL-6 and IL-8,




Group A: fish fed
fishmeal followed by
fish fed plant protein
each for 10 weeks
(TG – 117, Total-C -
233, LDL-C - 152)
Fishmeal (1 g n-6 PUFA)
The group initially receiving plant
protein fed fish experienced
reductions in cholesterol occurring
10 weeks after subsequently fed fish
fed fishmeal
Group B: fish fed
plant protein
followed by fish fed
fishmeal each for
10 weeks
(TG – 94, Total-C -

































Normolipidemic Subjects – Modified EPA and/or DHA Intake Moderately Hyperlipidemic Subjects – Modified EPA and/or DHA Intake




4 −26* 8 Group A 4.1 −9* 4 Mediterranean
Based
Hallund [32] Group B 2.3 9 4 Swedish Based
Group A 3.4 −14 8 Trout Based Sofi [42]
Group B 0.8 −6 8 Trout Based Group A 2.3 −2 10 High LA diet
Navas-Carretero
[34]
2.8 −3.1 8 Oily Fish Based Group B 2.3 −2 10 Moderate LA diet
Minihane [41] Group C 2.3 −12 10 Moderate LA diet
Group A 2 3 6 Moderate LA diet Group D 2.3 −2 10 High LA diet







Group A 0.33 2 8
Group B 0.33 1 4
Coates [38] 0.185 −27* 12
Normolipidemic Subjects – Modified ALA Intake Moderately Hyperlipidemic Subjects – Modified ALA Intake
Stuglin [39] 6.98 41* 4 Ground Flaxseed Dodin [28,
30]
8.53 3 52 Ground Flaxseed
Patenaude [40]
Group A 6.5 −11 4 Ground Flaxseed
Group B 6.5 13 4 Ground Flaxseed
Group C 5.74 −20 4 Flaxseed Oil
Group D 5.74 4 4 Flaxseed Oil
*Asterisks denotes studies which found significantly different changes in serum TG levels (p < 0.05)
Leslie et al. Lipids in Health and Disease  (2015) 14:53 Page 8 of 18differences between treatments, the diet providing 15 g
of n-6 PUFA produced a trend towards reduced total-c
and LDL-c by 3 % and 8 %, respectively, and a trend to-
wards elevated HDL-c by 8 % [41]. During a 10-week
cross-over study, participants consumed 90 g/day of
fishmeal- or plant protein-fed gilthead sea bream that
provided either 1 g or 2 g/day of n-6 PUFA, respectively,
while consistently providing 2.3 g/day of n-3 PUFA [42].
This study showed that individuals who first consumed
the fishmeal-fed gilthead sea bream had a reduction in
total-c, LDL-c and TG by 29.3 %, 21.6 % and 11.7 %, re-
spectively, prior to rebounding after 10 weeks of con-
suming plant protein-fed fish [42]. However, participants
who first consumed the plant protein-fed fish did not
experience reductions in any lipid markers following ei-
ther dietary intervention, except for a 5 % reduction in
total-c following the cross over period [42].Supplementation studies
Using the selection criteria previously described, 22 clin-
ical trials (1637 subjects in total) utilizing n-3 PUFA in a
supplement form were evaluated in the current review
(Table 3). These trials assessed the effect of n-3 PUFA
supplementation on blood lipid profiles in individuals
with normal and borderline high levels of TG, total-c,
and LDL-c. These studies included participants from
ages 18 to 75 years, with a treatment duration ranging
from 2 to 52 weeks. The main source of n-3 PUFA from
these studies was fish oil [43–59], which provided an ap-
proximate EPA:DHA ratio of 1.5:1. Five studies utilized
a DHA-rich oil from an algal source [59–63], and two
studies employed an EPA-rich oil from fish sources
[59, 64]. The studies encouraged participants to con-
sume n-3 PUFA supplements in the form of 1 to 12
capsules per day while maintaining normal dietary



















26 weeks TG levels increased 15 % in the
placebo group and decreased
2 % in the treatment group




0.18 g EPA +
0.12 g DHA








3 capsules of fish







52 weeks TG levels reduced 16.5 % by
1.8 g/day, and was unchanged
in both 0.45 g/day and 0.9 g/day
(sig)
No change in blood
pressure, arterial







a) 0.45 g n-3 PUFA
Vs.
b) 0.9 g n-3 PUFA




c) 1.8 g n-3 PUFA
Vs.
Placebo
Hlais (2013) [45] 112 males Fish oil (FO)
capsules (Per
gram: 0.737 g of
n-3 PUFA: 0.495 g







After 6 weeks : No significant effects







A) 2 g of FO
TG was reduced by 15 %, 4 %,
10 % in Groups A, B, D,
respectively, and elevated by 6 %,
3 % in Groups C, E, respectively
(only group A was sig)
Vs.
B) 1 g of FO and
8 g of sunflower
oil
Vs.
Total-c and LDL-c was elevated
by 2-8 % in Groups A, B, C, E
(non-sig) and by 7 % and 13 % in
Group D, respectively (sig)
C) 2 g of FO and
8 g of sunflower
oil
Vs.
HDL-c was elevated by 4-6 % in
Groups A, C, D and reduced by
10 % and 3 % in Groups B, E,
respectively (non-sig)
D) 4 g of FO and
8 g of sunflower
oil
Vs.
After 12 weeks :
TG was reduced by 12 %, 12 %,
2 %, 5 % in Groups A, B, D, E
respectively, and elevated by 1 %
in Groups C (non-sig)
Total-c was elevated by 4 % in
Groups A, D, and reduced by
1 %, 4 % and 10 % in groups B,
C, E, respectively (only Group E
was sig)
E) 8 g of
sunflower oil
LDL-c was elevated by 3-7 % in
Groups A, B, D (non-sig) and
reduced by 5 % and 13 % in
Group C, E, respectively (only
Group E was sig)
HDL-c was elevated by 6 %, 2 %
in Groups A, D, respectively, and
reduced by 5-7 % in Groups B, C,
E, (non-sig)
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5 weeks TG reduced 12 % (sig) Systolic and Diastolic
blood pressure was
reduced by 5 %
Age: 51–72 1.5 g EPA, 1.05 g
DHA, and 0.45 g





Rizza (2009) [47] 25 females, 25
males
2 capsules of fish
oil (0.6 g EPA,





























12 weeks TG was reduced 31 % (sig)
Age: 30–70





LDL-C - 128) Vs.














5 weeks TG reduced 26 % in group
receiving 14 g of fish oil (sig) and









a) 14 g safflower





Group receiving safflower oil
alone experienced a 21 %
increase in TG levels
b) 7 g safflower
oil + 7 g fish oil
(1.45 g EPA +
DHA)
No change in LDL-c or total-c
Vs.
14 g fish oil





Fish oil: 4 g of




2 weeks Participants receiving Epanova
had reductions in TG, HDL-c and
LDL-c of 21 %, 5 % and 4 %,
respectively
Epanova raised plasma
total EPA + DHA
concentrations 3 times






Lovaza: 1.8 g of
EPA, 1.5 g of DHA
Participants receiving Lovaza had
reductions in TG and HDL-c
levels of 8 % and 7 %, respect-
ively, while raising LDL-c by 0.4 %
Epanova: 2.2 g of
EPA and 0.8 g of




31 Females Fish oil capsules




4 weeks TG was reduced 35-40 % in
groups receiving 0 g, 1 g and 2 g
of GLA (sig), and TG was reduced










All groups had reductions in
total-c of 1-9 %
1 g of GLA
LDL-c was reduced in all groups
by 2-13 %, except in the group
receiving 1 g of GLA (only sig in
the group receiving 2 g of GLA)Vs.
2 g of GLA
Vs.
4 g of GLA
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2 weeks TG was reduced 25 % in the
group receiving Seal oil and 21 %
in the group receiving Tuna oil
(sig)
CRP was reduced by
11 % and 25 % in the
groups receiving tuna
oil and fish oil,
respectively
Age: 20–50 Tuna oil (0.21 g of
EPA, 0.03 g of




LDL-C - 134) Vs.
Seal oil (0.34 g of
EPA, 0.23 g of
DPA, 0.45 g of
DHA)
LDL-c was elevated through both





20 Males 9 capsules of fish
oil:1.05 g EPA,
0.75 g, DHA, and






4 weeks TG was reduced 10 % (sig) Treatment lowered
integrin activation, as
well as plasma levels of
fibrinogen and factor V











(46 % and 39 % of





12 weeks There was no significant change
in TG levels from baseline within
each group, however, a
significant dose response was
noted. n-3 PUFA provided at 2 g
and 4 g per day resulted in TG




Total-C - 211) 1 g of n-3 PUFA/
day
Vs.
2 g of n-3 PUFA/
day
Vs.
4 g of n-3 PUFA/
day









4 weeks n-3 PUFA produced a 26 %
reduction in serum TG levels (sig)
2.4 g EPA + 1.6 g
of DHA
n-3 PUFA produced a 5 %









66 males 10 capsules of fish






8 weeks TG levels were reduced 19 %
with high LA intake (sig) and












LA in diet or low
LA in diet




29 Males fish oil capsules Double-blind,
parallel, dietary
intervention
6 weeks TG was reduced 20 % and 25 %
in high and moderate groups,
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Table 3 Studies assessing the lipid lowering effects of n-3 PUFA utilizing a supplement (Continued)
Kaul (2008) [58] 54 females, 34
males






12 weeks Fish oil produced a 4 % and 7 %
increase in total-c and LDL-c,
respectively
No significant change





Fish oil (0.606 g of
n-3 PUFA; 0.242 g
of DHA + 0.352 g
of EPA)
Flaxseed oil produced a 4 % and






Hempseed oil produced a 4 %
increase in both total-c and LDL-
c and an 18 % increase in TG
Vs.
Flaxseed oil




ALA,1.14 g of LA)
Vs.
Sunflower oil











4 weeks EPA treatment: TG decreased
22 % (sig)





DHA treatment: TG decreased
38 % (sig)
4.9 g DHA
Total-c decreased (p = 0.06)
Vs.
Placebo












4 weeks TG decreased from baseline 14 %
(sig)





1.5 g DHA + 0.6 g
DPA
Vs.
HDL-c increased by 9 % (sig)
Placebo












4 weeks DHA decreased TG by 8 % (sig). DHA was able to
reduce resting heart
rate by 7 %
Age: 45–70
2.8 g of DHA
DHA elevated HDL-c by 8 %,
total-c by 4 % and reducing
LDL-c by 8 %
(TG - 132,
Total-C – 216,
LDL-C – 125) Vs.
Placebo (corn and
soy oil mixture)





providing 6 g of





6 weeks DHA decreased TG by 18 %,
Total-c by 3 % and LDL-C by 3 %
while elevating HDL-C by 6 %
No changes in levels of
urinary estrogen
metabolites, or markers
























8 weeks TG reduced 23 % in the group




0.94 g of DHA
Total cholesterol, LDL-c and HDL-
c increased 6-11 % in the group




LDL-C – 97) Placebo (olive oil) No changes in the placebo
group
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12 weeks TG levels were reduced ~25 %
after 1.35, 2.7 or 4.05 g of EPA




a) 1.35 g EPAAge: Young,
18–42;
Old, 53–70 Vs.
b) 2.7 g EPA
(TG - 82,
Total-C – 162,
LDL-C – 103) Vs.
No effect on HDL-c, LDL-c, or
total-c in any group
c) 4.05 g EPA
Vs.
Placebo
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PUFA. As shown in Table 4, fasting TG levels were reduced
following supplementation with EPA and/or DHA exclu-
sively in 30/34 experimental arms within the 22 studies
(i.e. 88 % of the interventions evaluated, without taking stat-
istical significance into account) and post-supplementation
TG levels were significantly lowered from baseline in 23 of
the 34 aforementioned experimental arms (i.e. 68 % of the
interventions; however, one study did not analyze for an in-
group difference in serum lipid levels from baseline to post-
supplementation [62]).
The magnitude of the n-3 PUFA-mediated TG-lowering
effect varied depending on the supplementation dose and
the study duration. Low doses such as 0.3-0.9 g/day of n-
3 PUFA for 12–52 weeks did not consistently produce a
significant reduction in TG levels [43–45, 63]. While stud-
ies solely providing n-3 PUFA in doses < 1 g/day (EPA,
DHA or both) significantly lowered fasting TG by 8-38 %
[44–55, 59, 61, 62, 64]. In a dose–response study, 1.8 g/
day of EPA and DHA for 52 weeks was sufficient to lower
TG levels by 16.5 %, whereas 0.45 and 0.9 g/day did not
affect fasting TG levels [44]. A second study demonstrated
a significant dose–response effect whereby 1 g/day of
marine derived n-3 PUFA produced an elevation in TG
levels by 9 %, while 2 and 4 g/day of n-3 PUFA for
12 weeks produced decreases in TG levels of 15 % and
20 %, respectively [54]. However, none of the aforemen-
tioned doses produced a significant change from baseline
values [54].
Two studies investigated the effect of fish oil based n-3
PUFA supplementation combined with a background diet
that was either high or moderate in n-6 PUFA, specifically
linoleic acid (18:2 n-6, LA) [56, 57]. In an 8 week study,
3.1 g/day of n-3 PUFA resulted in a 19 % and a 51 % re-
duction in TG levels while consuming either a high or
moderate n-6 PUFA background diet, respectively [56].
Similarly, participants of a 6 week study, stratified to a high
or moderate LA background diet found that 2.5 g/day of
EPA and DHA benefited both groups with similar reduc-
tions in TG levels of 20 % and 25 %, respectively [57].Studies that utilized an algal source of DHA consist-
ently demonstrated the TG-lowering effects of the sup-
plement [59–63]. Three 4-week studies, providing 1.5,
2.8 and 4.9 g/day of DHA, found significant reductions
in TG levels of 14 %, 8 % and 38 %, respectively [59–61].
Further, a 6-week study providing 2.4 g/day of algal-
derived DHA showed a significant 18 % reduction in
TG levels compared to a placebo [62]. Additionally, a
study providing only 0.94 g/day of DHA, but for
8 weeks, noted a significant 23 % reduction in TG
levels [63].
Blood cholesterol levels were also examined in the 22
supplementation studies within the current review, and
only two studies [48, 60] observed modest n-3 PUFA-
induced increases in HDL-c levels that were signifi-
cantly different from baseline. Thus, total-c, LDL-c,
and HDL-c remained largely unchanged with n-3 PUFA
supplementation. A modest reduction in total-c oc-
curred with 4.9 g/day of DHA, yet this difference was
not statistically significant [59]. Additionally, only 1
study produced a significant 11 % reduction in LDL-c
levels following 4 weeks of supplementation with 4 g/
day of n-3 PUFA, however, this effect was produced
with an additional 2 g/day supplement of gamma-
linolenic acid (18:3 n-6, GLA) [51].
Discussion
This review indicates that the established TG-lowering
effect of n-3 PUFA in hyperlipidemic individuals is
maintained within populations who are normolipidemic
to borderline hyperlipidemic. Studies in which partici-
pants consumed EPA and/or DHA or fish consistently
reported lower blood TG levels in comparison to those
studies in which participants consumed plant-based
sources of n-3 PUFA. Overall, the studies involving diet-
ary interventions evaluated within the current review
suggest that a TG-lowering effect of marine based n-3
PUFA is produced in healthy individuals upon the con-
sumption of ≥ 4 g/day of n-3 PUFA. In contrast, the sup-
plementation studies assessed within the current review


















Normolipidemic Subjects - EPA and/or DHA Supplements Moderately Hyperlipidemic Subjects – EPA and/or DHA Supplements
Cazzola [64] Buckley [59]
Group A 4.05 −30* 12 Group A 4.9 −8* 4
Group B 4.05 −25* 12 Group B 4.8 −22* 4
Group C 2.7 −25* 12 Laidlaw [51]
Group D 2.7 −33* 12 Group A 4 −40* 4
Group E 1.35 −22* 12 Group B 4 −39* 4 1 g of γ-linolenic
acid




Group D 4 −7 4 4 g of γ-linolenic
acid
Group A 3.25 −51* 8 Low LA diet Di Stasi [54]
Group B 3.25 −19* 8 High LA diet/Olive
Oil
Group A 4 −20 12
Nilsson [46] 3 −12* 5 Group B 2 −15 12
Hlais [45] Group C 1 9 12
Group A 2.95 −10 6 8 g of Sunflower Oil Stark [55] 4 -26* 4
Group B 2.95 −2 12 8 g of Sunflower Oil Offman [50]
Group C 1.47 −15* 6 Group A 3.3 −8 2
Group D 1.47 6 6 8 g of Sunflower Oil Group B 3 −21 2
Group E 1.47 −12 12 Vanschoonbeek
[53]
3 −10* 4
Group F 1.47 1 12 8 g of Sunflower Oil Ciubotaru [49]
Group G 0.74 −4 6 8 g of Sunflower Oil Group A 2.9 −26* 5
Group H 0.74 −12 12 8 g of Sunflower Oil Group B 1.45 −4 5 7 g of Safflower
Oil
Brady [57] Stark [61] 2.8 −20* 4
Group A 2.5 −25* 6 Moderate LA diet/
Olive Oil
Lovegrove [48] 2.5 −31* 12
Group B 2.5 −20* 6 High LA diet - Corn
Oil
Sanders [44]
Wu [62] 2.4 −18* 6 Group A 1.8 −17* 52
Sanders [60] 2.1 −21 4 Group B 0.9 0 52
Rizza [47] 2 −26* 12 Group C 0.45 0 52
Geppert
[63]
0.94 −23* 8 Mann [52]
Kaul [58] Group A 1.05 −21* 2
Group A 0.61 0 12 Group B 1.02 −25* 2
Fakhrzadeh [43] 0.3 −2 26
Normolipidemic Subjects - ALA Supplements
Kaul [58]
Group B 1.02 0 12 Flaxseed Oil; 0.28 g
of LA
Group C 0.37 15 12 Hempseed Oil; 1.02 g
of LA
*Asterisks denotes studies which found significantly different changes in serum TG levels (p < 0.05)
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(derived from either fish or algal oil) is required to con-
fer a similar benefit as observed in the dietary
interventions.
Within the past 5 years, the European Food Safety
Authority (EFSA), the AHA and the Food Standards -
Australia and New Zealand (FSANZ) organization have
all recognized n-3 PUFA as a preventative measure
against the development of CVD, primarily by reducing
risk factors for CVD, including elevated blood TG
levels [12–15]. The EFSA established and substantiated
a health claim in 2010 indicating the consumption of
2 g of EPA/DHA per day has the ability to maintain
normal blood TG concentrations [12, 13]. Furthermore,
the AHA released a statement in 2011 indicating that a
daily dosage of 2–4 g of n-3 PUFA, specifically EPA
and DHA, confers a 25-30 % decrease in serum TG
levels [14].
The health claim by the EFSA and the statement by the
AHA are largely based on the findings of a systematic
review by W.S. Harris [19]. This review stratified studies
comparing participants with either healthy (serum levels <
177 mg/dL) or elevated levels (serum levels ≥ 177 mg/dL)
of serum TG; relative to the upper limit for serum TG of
200 mg/dL utilized in the current review [19]. However, in
the review by Harris, a quarter of the studies assessing par-
ticipants with healthy baseline TG levels contained a hyper-
cholesterolemic population (serum TC ≥ 240 mg/dL).
Nonetheless, the results indicated that 3–4 g/day of EPA
and/or DHA produced a 25-34 % decrease in serum TG
levels [19]. This finding is supported by a later systematic
review which reported that individuals with either border-
line high or high levels of serum TG (according to AHA
guidelines) experienced reductions in TG levels of ~20 %
and ~30 %, respectively, when consuming 4 g/day of EPA
and/or DHA [18].Fig. 2 The percent change in serum TG levels from baseline values in norm
either through the diet or supplemental forms. Shaded markers indicate chThe previous reviews indicate that marine based n-3
PUFA can reduce serum TG levels; however, they pri-
marily focused on supplementation studies within dys-
lipidemic populations. An earlier review by W. S. Harris,
than the 1997 study previously discussed, included diet-
ary intervention studies and produced findings similar to
those of the current review. Overall, consuming n-3
PUFA through dietary forms primarily showed a trend
in TG reductions, while a significant effect was only ob-
served when large amounts of n-3 PUFA were consumed
(as observed in Table 2, ≥ 4 g/day of n-3 PUFA) and the
effects of ALA supplementation were highly variable
[17]. W. S. Harris concluded that this inconsistency in
the ability of n-3 PUFA to reduce serum TG levels dur-
ing dietary interventions was likely due to the manipula-
tion of multiple variables as the food source was not
highly controlled between studies [19]. The lack of a
consistent study design for elevating n-3 PUFA con-
sumption through dietary modifications continues to be
a limitation for the field. This constraint reduces the
ability to evaluate an exact dosage and source of EPA
and/or DHA required to significantly, and routinely,
lower serum TG levels across all populations.
Several reviews have repeatedly shown an effect of
EPA and/or DHA in lowering TG levels during supple-
mentation trials [17, 19–24]. Based on the current re-
view, when ≥ 1 g/day of EPA and/or DHA is consumed
by individuals, without any other increases in dietary fat
intake, an 8-40 % reduction in TG levels can be ob-
served, as shown in Table 4. The apparent presence of a
lipid-lowering dose–response to marine derived n-3 PUFA
intake, demonstrated in the study by Di Stasi et al. [54],
suggests additional benefits are attainable when supplemen-
tation is raised as high as 4.9 g/day [54]. Figure 2 summa-
rizes the TG-lowering effects of individuals consuming
ALA, EPA, DHA or some combination of these n-3 PUFAolipidemic and borderline hyperlipidemic subjects receiving n-3 PUFA
anges from baseline that are statistically significant (p < 0.05)
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lights the consistent lipid-lowering effect of EPA and DHA;
studies providing ALA remain inconclusive. Additionally,
Fig. 2 indicates that as the dose of EPA and/or DHA in-
creases, in both supplementation and dietary intervention
studies, a concurrently larger reduction in TG levels is ob-
tained. Furthermore, Fig. 2 shows neither EPA and/or DHA
significantly raised TG levels from baseline in either supple-
mentation or dietary intervention studies.
Based on the present review, the beneficial effects of
n-3 PUFA, specifically EPA and DHA, which have been
substantiated in hyperlipidemic individuals, extend to in-
dividuals with normal to borderline high levels of serum
lipids. In summary, using select search terms and cri-
teria, our review of the existing evidence has shown that
consumption of ≥ 4 g/day of n-3 PUFA through marine
and EPA and/or DHA-enriched food sources, or 1–5 g/
day of EPA and/or DHA in supplement form, has the
ability to reduce serum TG by 9-26 % and 4-51 %, re-
spectively, in normolipidemic to borderline hyperlipid-
emic and otherwise healthy individuals. This provides
evidence that the consumption of marine based n-3
PUFA is not only extremely useful to treat dyslipidemia,
but is also beneficial for otherwise healthy populations
in the prevention of hyperlipidaemia and may subse-
quently reduce the risk of developing CVD.
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